| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/29/2000 | US6110672 Peripheral nervous system specific sodium channels, DNA encoding therefor, crystallization, X-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof |
| 08/29/2000 | US6110666 Detection of regulatory sequences; transforming a cell with a genetically engineered expression vector, monitor preferential gene expression in cell |
| 08/29/2000 | US6110664 Antisense inhibition of G-alpha-S1 expression |
| 08/29/2000 | US6110507 Human 3-hydroxyisobutryl-coenzyme a hydrolase |
| 08/29/2000 | US6110487 Method of making porous keratin scaffolds and products of same |
| 08/29/2000 | US6110468 Respiratory syndrome virus for swine |
| 08/29/2000 | US6110466 Modified plant viruses as vectors |
| 08/29/2000 | US6110463 Anti-Cryptosporidium parvum preparations |
| 08/29/2000 | US6110460 Methods of using morphogen analogs |
| 08/29/2000 | US6110459 Grafting of myocardium tissues |
| 08/29/2000 | US6110209 Method and paste for articular cartilage transplantation |
| 08/29/2000 | CA2086754C Treatment of human lactation failure |
| 08/29/2000 | CA2034487C Dna sequences, vectors, and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi |
| 08/29/2000 | CA2015687C Human serum albomin fusion polypeptide |
| 08/29/2000 | CA2010275C Pancreatic islet cell antigens obtained by molecular cloning |
| 08/29/2000 | CA1341090C Vampire bat plasminogen activators |
| 08/25/2000 | CA2263042A1 Treatment of edema |
| 08/24/2000 | WO2000049170A1 MURINE 11cby RECEPTOR |
| 08/24/2000 | WO2000049160A1 Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders |
| 08/24/2000 | WO2000049153A1 Fucosyl transferase gene |
| 08/24/2000 | WO2000049147A1 Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy |
| 08/24/2000 | WO2000049145A2 Hematopoietic genes hzf and hhl and polypeptides encoded thereof |
| 08/24/2000 | WO2000049135A2 Substrate for cell growth |
| 08/24/2000 | WO2000049132A2 Uses of transgenic animals containing a type x collagen mutant |
| 08/24/2000 | WO2000049043A2 Human lipid-associated proteins |
| 08/24/2000 | WO2000049042A1 nadE |
| 08/24/2000 | WO2000049041A1 Protein preparations |
| 08/24/2000 | WO2000049040A2 Antimicrobial/endotoxin neutralizing polypeptide |
| 08/24/2000 | WO2000049038A2 Synthetic peptide of regulatory virus protein r (vpr) of human immunodeficiency virus type 1 (hiv-1) and the utilization thereof |
| 08/24/2000 | WO2000049037A1 Growth hormone secretagogues |
| 08/24/2000 | WO2000049033A1 yybQ |
| 08/24/2000 | WO2000049008A1 Di- and tripeptide nitrile derivatives as inhibitors of cathepsin l and cathepsin s |
| 08/24/2000 | WO2000048635A1 Novel albumin-free factor viii formulations |
| 08/24/2000 | WO2000048631A2 Adjuvant and cell maturation agent |
| 08/24/2000 | WO2000048627A1 Inhibitors of separin, method for identifying them and uses |
| 08/24/2000 | WO2000048626A2 Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammation associated with pulmonary disease |
| 08/24/2000 | WO2000048625A2 Inhibitors for use in hemostasis and immune function |
| 08/24/2000 | WO2000048624A2 Utilization of orosomucoid in order to produce a pharmaceutical preparation |
| 08/24/2000 | WO2000048623A1 Novel amide derivatives as growth hormone secretagogues |
| 08/24/2000 | WO2000048622A2 Method for inhibiting inflammatory responses |
| 08/24/2000 | WO2000048621A2 Methods and compositions for regulating protein-protein interactions |
| 08/24/2000 | WO2000048620A1 Yeast cell wall peptides and antibodies thereto |
| 08/24/2000 | WO2000048619A1 Combined therapy of diterpenoid triepoxides and trail for synergistic killing of tumor cells |
| 08/24/2000 | WO2000048618A1 Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin |
| 08/24/2000 | WO2000048617A2 Connective tissue softening |
| 08/24/2000 | WO2000048614A2 Method for producing anti-tumor th1 cells |
| 08/24/2000 | WO2000048595A1 A novel anti-angiogenic agent comprising at least one kringle region and an upstream pre-activation domain of plasminogen |
| 08/24/2000 | WO2000048593A1 Epoxide hydrolase complexes and methods therewith |
| 08/24/2000 | WO2000048558A1 Modified calycins |
| 08/24/2000 | WO2000048551A1 Natural antioxidant compositions, method for obtaining same and cosmetic, pharmaceutical and nutritional formulations thereof |
| 08/24/2000 | WO2000048464A1 Ng2/hm proteoglycan-binding peptides that home to angiogenic vasculature and related methods |
| 08/24/2000 | WO2000032039A8 PURIFIED AND ISOLATED piwi FAMILY GENES AND GENE PRODUCTS AND METHODS EMPLOYING SAME |
| 08/24/2000 | WO2000029550A3 Low oxygen culturing of central nervous system progenitor cells |
| 08/24/2000 | WO2000027380A3 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
| 08/24/2000 | WO2000025745A3 Irrigation solution and method for inhibition of pain and inflammation |
| 08/24/2000 | WO2000025138A3 Methods of diagnosing or prognosing alzheimer's disease |
| 08/24/2000 | WO2000023100A9 Genes and proteins predictive and therapeutic for renal disease and associated disorders |
| 08/24/2000 | WO2000023095A3 Method of modulating hair growth |
| 08/24/2000 | WO2000022112A9 Stabilized bioactive peptides and methods of identification, synthesis and use |
| 08/24/2000 | WO2000021987A9 A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease |
| 08/24/2000 | WO2000021569A3 Macromolecular active substance conjugates and a method for the production thereof |
| 08/24/2000 | WO2000020434A9 Cadherin-like asymmetry protein-1, and methods for its use |
| 08/24/2000 | WO2000020025A9 Akt compositions for enhancing survival of cells |
| 08/24/2000 | WO2000020018A9 Kappa-a conopeptides and uses therefor |
| 08/24/2000 | WO2000018922A8 Human carbohydrate-associated proteins |
| 08/24/2000 | WO2000018917A9 α-SYNUCLEIN SUPER-MUTANTS ACCELERATE α-SYNUCLEIN AGGREGATION |
| 08/24/2000 | WO2000016800A9 Methods of treating chronic pain |
| 08/24/2000 | WO2000015797A3 Compositions and methods for the treatment of immune related diseases |
| 08/24/2000 | WO2000015783A9 ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO β1-ADRENOCEPTOR-SPECIFIC mRNA AND METHODS OF USE |
| 08/24/2000 | WO2000015660A9 Target of rnaiii activating protein (trap) |
| 08/24/2000 | WO2000015246A9 Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
| 08/24/2000 | WO2000012685A3 Genes associated with neurotransmitter processing |
| 08/24/2000 | WO2000004917A9 USE OF HC gp-39 IN IMMUNE DISEASES |
| 08/24/2000 | WO1999067379A3 Structured antisense nucleic acid molecules |
| 08/24/2000 | WO1999057280A3 Neisseria meningitidis antigens and compositions |
| 08/24/2000 | WO1999046371A3 Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery |
| 08/24/2000 | WO1998024898A3 Therapeutic composition comprising the kal protein and use of the kal protein |
| 08/24/2000 | WO1998007308A3 Thrombin inhibitors |
| 08/24/2000 | WO1998000439A3 Multivalent compounds for cross-linking receptors and uses thereof |
| 08/24/2000 | DE4193302C2 Verwendung rekombinanter Antikörper spezifisch für TNF-alpha Using recombinant antibody specific for TNF-alpha |
| 08/24/2000 | DE19906744A1 Pharmaceutical composition useful for tumor therapy comprises tumor-reactive helper T cells that produce high levels of interferon gamma and little or no interleukin-4 |
| 08/24/2000 | CA2634674A1 Novel albumin-free factor viii formulations |
| 08/24/2000 | CA2371872A1 Methods and compositions for regulating protein-protein interactions |
| 08/24/2000 | CA2371799A1 Yeast cell wall peptides and antibodies thereto |
| 08/24/2000 | CA2362970A1 Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy |
| 08/24/2000 | CA2362664A1 Utilization of orosomucoid in order to produce a pharmaceutical preparation |
| 08/24/2000 | CA2362538A1 Secreted proteins and polynucleotides encoding them |
| 08/24/2000 | CA2362346A1 Natural antioxidant compositions, method for obtaining same and cosmetic, pharmaceutical and nutritional formulations thereof |
| 08/24/2000 | CA2362330A1 A novel anti-angiogenic agent comprising at least one kringle region and an upstream pre-activation domain of plasminogen |
| 08/24/2000 | CA2362303A1 Growth hormone secretagogues |
| 08/24/2000 | CA2362300A1 Human lipid-associated proteins |
| 08/24/2000 | CA2362290A1 Novel amide derivatives as growth hormone secretagogues |
| 08/24/2000 | CA2362284A1 Modified calycins |
| 08/24/2000 | CA2361273A1 Inhibitors for use in hemostasis and immune function |
| 08/24/2000 | CA2262056A1 Composition, methods and reagents for the synthesis of a soluble form of human pex |
| 08/23/2000 | EP1029921A1 Serpin resistant chymotrpsin superfamily proteases, particularly PAI-1 resistant t-PA, complementary inhibitor mutants; compositions; genes; expressions |
| 08/23/2000 | EP1029918A1 Killer t cell receptor recognizing human immunodeficiency virus |
| 08/23/2000 | EP1029916A1 Human lysophosphatidic acid receptor and use thereof |
| 08/23/2000 | EP1029870A2 Hybrid Immunoglobulins |
| 08/23/2000 | EP1029869A1 Endothelin converting enzyme inhibitors |